Efficacy of SGLT2 inhibitors as additional treatment in Japanese type 2 diabetic patients: second or third choice?
Efficacy of SGLT2 inhibitors as additional treatment in Japanese type 2 diabetic patients: second or third choice?
复制标题
DOI：
10.1186/s13104-022-06010-6
复制
发表时间：
2022-03-29
影响因子：
1.8
通讯作者：
Shimomura K
中科院分区：
文献类型：
--
作者：
Fujiwara M;Shimizu M;Maejima Y;Shimomura K
由于2型糖尿病(T2D)的增加，接受多种抗糖尿病药物治疗的患者数量也在增加。根据最近的治疗指南建议，对于控制不佳的T2D患者，钠-葡萄糖共转运体2(SGLT2)抑制剂将作为目前使用的抗糖尿病药物的补充治疗。在这里，我们评估了在目前的治疗中加入SGLT2抑制剂与二甲双胍和/或二肽基肽酶-4(DPP4)抑制剂在日本T2D患者中的疗效。血糖控制不良的日本T2D受试者接受二甲双胍(n = 10)、DPP4抑制剂(n = 11)或两者同时治疗(n = 28)，并需要额外治疗。比较治疗前和治疗后6个月的糖化血红蛋白水平。加入SGLT2抑制剂后，所有组的HbA1c水平均显著降低。糖化血红蛋白(HbA1c)的变化在三组间无显著差异。目前的数据表明，在治疗日本T2D患者时，在二甲双胍和/或DPP4抑制剂的基础上加用SGLT2抑制剂同样有效。
Due to the increase of type 2 diabetes (T2D), the number of patients in treatment with multiple anti-diabetic agents is increased. According to the recent recommendation of treatment guidelines, sodium-glucose cotransporter 2 (SGLT2) inhibitors would be used as additional treatment to the currently administered anti-diabetic drugs for poorly controlled T2D patients. Here, we assessed the efficacy of SGLT2 inhibitors added to the current treatment with metformin, dipeptidyl peptidase-4 (DPP4) inhibitors, or both in Japanese T2D patients. Japanese T2D subjects with poor glucose control, who were treated with metformin (n = 10), DPP4 inhibitors (n = 11), or both (n = 28) and who were in need of additional treatment, were recruited. HbA1c levels before and 6 months after addition of SGLT2 inhibitor treatment were used to compare the effectiveness. The HbA1c levels after addition of SGLT2 inhibitors significantly decreased in all groups. The change in HbA1c levels (delta HbA1c) showed no significant difference between the three groups. The present data indicated that addition of SGLT2 inhibitors to metformin and/or DPP4 inhibitors is equally effective in the treatment of Japanese T2D patients.
登录
查看更多内容
影响因子：
8.2
作者：
Chaturvedi, N;Stevens, LK;Lu, M
通讯作者：
Lu, M
DOI：
10.1111/dom.14535
发表时间：
2021-12
期刊：
Diabetes, obesity & metabolism
影响因子：
--
作者：
通讯作者：
--
影响因子：
5.8
作者：
Vilsboll, T;Krarup, T;Holst, JJ
通讯作者：
Holst, JJ
影响因子：
3.8
作者：
Odawara, Masato;Yoshiki, Mika;Sano, Misako;Hamada, Izumi;Lukashevich, Valentina;Kothny, Wolfgang
通讯作者：
Kothny, Wolfgang
影响因子：
5.1
作者：
Fukushima, M;Suzuki, H;Seino, Y
通讯作者：
Seino, Y